NCT04042714: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

NCT04042714
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine Tumor (NET)
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have prior treatment with a platinum containing regimen
Exclusions: 
https://ClinicalTrials.gov/show/NCT04042714

Comments are closed.

Up ↑